INTRODUCTION
Cholesterol-lowering drugs are currently the most widely used therapeutics for the treatment of atherosclerosis and dyslipidemia. In addition to LDL-lowering agents such as statins, novel therapeutics are also being developed that are targeting the cholesterol balance and turnover through alternate mechanisms. The cholesteryl ester transfer protein (CETP) appears to be a promising pharmacological target, as it governs the equilibrium between the LDL and HDL cholesterol, and inhibition of CETP is thought to provide an effective mechanism that is able to shift the cholesterol balance towards the "good" HDL cholesterol (Linsel-Nitschke & Tall, 2005; Tall, 2007) .
The validity of HDL as a surrogate for cardiovascular risk has recently been questioned (Tuteja & Rader, 2014) , and initial efforts to develop CETP inhibitors for increasing HDL levels clinically have been hampered either by unwanted side effects, such as blood pressure increases caused by Pfizer's torcetrapib (Barter et al, 2007) , or by lack of efficacy, as was the case for Roche's dalcetrapib (Schwartz et al, 2012 ) and Lilly's evacetrapib (Nicholls et al, 2015) .
Nonetheless, pharmaceutical companies continue to invest significant resources into the development of safe and effective CETP inhibitors. To assess whether patients treated with CETP inhibitors will have a long-term benefit (e.g. by lowering the risk of cardiovascular events and thus decreasing mortality), long-term outcome trials of Merck's investigational compound anacetrapib (MK-0859, Figure 1 ) are currently ongoing.
Anacetrapib thus far has been shown to have a favorable safety and efficacy profile in humans. In addition to lowering LDL and raising HDL, the Phase III DEFINE trial demonstrated that CETP inhibition by anacetrapib was well-tolerated and anacetrapib was devoid of torcetrapib-like liabilities such as blood pressure increases (Krishna et al, 2008; Bloomfield et 2009; Gotto et al, 2014 a, b) . However, anacetrapib exhibits complex accumulation and washout kinetics in circulation in humans. As the clinical development of anacetrapib progressed and patients were treated for longer duration, the terminal half-life appeared to be longer than was predicted from initial studies with shorter treatment duration. (Gutstein et al, 2012; Gotto et al, 2014; Merck internal data) Understanding the causes underlying the long terminal half-life is crucial in order to fully characterize the pharmacokinetic properties of anacetrapib. Given the neutral lipophilic properties of anacetrapib, the high affinity to adipose tissue might contribute to the accumulation and retention of the drug in the body, such that a "drug depot" might be formed in the adipose upon multiple dosing, which would ultimately drive systemic pharmacokinetics and be responsible for the prolonged half-life in plasma. There is a considerable knowledge gap regarding how adipose disposition correlates to the long terminal half-life, and the question remains whether or not binding to plasma CETP would as well be a determinant of plasma halflife. In order to gain further insight into the long terminal half-life of anacetrapib, we established a preclinical model to delineate the impact of adiposity and CETP binding on the accumulation and washout kinetics of anacetrapib.
Since rodents naturally lack CETP, it was necessary to utilize a transgenic animal model in order to examine the impact of CETP. To that end, a preclinical in vivo experiment was conducted using wild type mice (lacking human CETP), CETP transgenic mice (expressing human CETP transgene) that were fed either a normal or a high-fat diet to increase adiposity.
Mice bearing the CETP transgene of the natural flanking region (NFR) have been well characterized (Masucci-Magoulas et al, 1995) . Furthermore, diet-induced obese (DIO) mice (fed on high-fat diet for two months) have previously been described as animal models to investigate This article has not been copyedited and formatted. The final version may differ from this version. 
MATERIAL AND METHODS

Chemicals and Dose Preparation
Anacetrapib (MK-0859) was provided by the GMP Group, Process Chemistry, Merck
Research Laboratories (MRL). The PO dose formulation was prepared as an emulsion as follows. The compound was dissolved in Imwitor-742:Tween-80 (1:1, w:w) at a starting concentration of 10 mg/mL, and sonicated for 25 min. The preparation was diluted 1:4 with water to yield a final concentration of 2 mg/mL, vortexed, sonicated for five minutes, then stirred prior to dosing.
Animal Studies
All experiments were performed according to procedures approved by the Merck A diagram of the study design is depicted in Figure 2 . Anacetrapib was administered PO (via gastric gavage) once daily (QD) at a dose of 10 mg/kg for six weeks (42 days) to the above subgroups of mice under fasted conditions (n = 50 per subgroup at the time of initial dosing following PO dosing) for a full blood PK profile on the respective sampling day. At the terminal time point (72 hr), the mice were sacrificed, and liver, brain, brown adipose and epididymal white adipose tissue were collected and snap-frozen in liquid nitrogen. Whole blood was also collected for measurement of trough drug concentrations (C 72h ).
At 4, 10, 16, 24 and 35 weeks following cessation of dosing (henceforth termed "postdose" period, corresponding to 70, 112, 154, 210 and 287 days since beginning of QD dosing), five mice per subgroup were sacrificed, and whole blood, liver, brain, brown adipose and epididymal white adipose tissue were collected at a single time point and processed as described above.
Sample Preparation and Bioanalysis
Anacetrapib and its 
Software and Calculations
Chromatographic data were acquired and peak areas integrated using the Sciex Analyst® software (Version 1.4.2, AB Sciex, Ontario, Canada). Concentration data for the calibration standards, QC samples, and study samples were determined using Watson LIMS (Version 7.3, Thermo LabSystems Inc., Philadelphia, PA).The peak area ratios of analyte to IS were plotted as a function of the nominal concentrations of analyte. Standard calibration curves were established in each matrix with ranges from 0.25-1000 ng/mL for MK-0859 low concentration matrices and 10-10000 ng/mL for high concentration matrices and were constructed using linear (weighted
portion of the AUC from the last measurable concentration to infinity was estimated by C t /k e , where C t represents the last measurable concentration and k e is the elimination rate constant. The latter was determined from the concentration versus time curve by linear regression at the terminal phase of the semi-logarithmic plot. The terminal half-life (T½) was calculated as 0.693/k e .
For the time period following cessation of QD dosing ("post-dose" period), the washout profiles were obtained by plotting the mean blood and tissue concentrations from the single time point collections on weeks 4, 10, 16 (for blood: 18), 24 and 35 post-dose, corresponding to 70,
RESULTS
Pharmacokinetics of Anacetrapib during 42-Day Dosing
Anacetrapib was dosed orally for 42 days in WT lean, WT DIO, NFR lean and NFR DIO mice. From the pharmacokinetic data collected over the dosing period, moderate accumulation was seen in the systemic exposures for all subgroups, with up to 1.8-fold increases in mean AUC 0-24h and less than 1.5 fold increases in mean C max (Table 1 and Figure 3 ). The average 72-hour blood concentrations were 3-to 9-fold higher on Day 42 compared to Day 1. On Day 15
and Day 28, the 72-hour blood concentrations were 2-fold to 7-fold higher compared to Day 1 (data not shown).
Accumulation and Elimination Kinetics of Anacetrapib in Mouse Blood and Tissues
Upon QD dosing for 42 days, the subgroups of mice exhibited differences in terms of the In liver, drug accumulation was in the range of two-to four-fold. Drug levels on Day 42
in the livers of DIO mice were in the range of 29 to 42 μM, about 100-fold higher than those in livers of lean animals ( Figure 6 ).
As the PK profiles of NFR mice were overlapping with those of WT mice (which was the case for lean as well as DIO mouse groups), it appears that the presence of CETP (unlike the degree of adiposity) did not impact the accumulation of the drug in adipose and liver.
Levels of anacetrapib in brain were generally very low (<0.1 μM), and were subject to high inter-animal variability, such that a clear trend of accumulation could not be seen (Figure 7) . The
This article has not been copyedited and formatted. The final version may differ from this version. residual drug levels at the end of the 35-week post-dose period were below quantitation limit for WT lean mice, and ranged from 0.002 to 0.02 μM in the other subgroups of mice.
Terminal Half-Life of Anacetrapib upon Multiple Dosing
Since the elimination rate of anacetrapib from white adipose tissue was extremely slow, the sampling duration of 35 weeks was not sufficient to capture the true terminal phase of anacetrapib elimination. Therefore the estimates of T½ based on observed elimination may not be entirely accurate; however they represent a semi-quantitative assessment of elimination kinetics of anacetrapib in each tissue.
The estimated T½ values of anacetrapib in mouse blood and tissues were generally very long, in the range of 40 to 300 days (Table 2 ). In blood, anacetrapib exhibited a 3-fold to 7-fold longer T½ in WT DIO, NFR lean and NFR DIO mice as compared to WT lean mice, suggesting that both adipose partitioning and binding to CETP have a potential role in determining the blood T½. The T½ of anacetrapib in brown adipose tissue appeared to be similar across mouse strains (~100 to 150 days). In white adipose tissue, the T½ was estimated to be 171 days and 277 days in WT DIO and NFR DIO mice, respectively, whereas no reliable T½ estimate could be obtained from WT lean and NFR lean mice due to absence of a terminal decay phase. In liver, the T½ was estimated to be 115 to 230 days. In brain, the T½ was highly variable, but shorter than in the other tissues (26 to 130 days).
Due to the terminal sampling mode (and hence the lack of individual time profiles) in the post-dose phase of the study, we relied on the mean concentration-time curves to obtain estimates of the terminal T½ in blood and tissues of the respective groups of mice. It was not possible to directly assess the intersubject variability, and standard error of T½ could not be calculated.
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DISCUSSION
This study provides evidence in a preclinical species that disposition of anacetrapib in adipose tissue plays a key role in the long-term accumulation and retention of the drug, and ultimately contributes to the observed long terminal T½ in systemic circulation. Of note, we measured the pharmacokinetic profile from mouse blood rather than plasma, as the measurement of the full concentration-time profile (0 to 72 hr on treatment days 1, 15, 28 and 42) required serial sampling from individual animals, which was possible only by sampling blood, due to limitations in the total blood volume available from mice.
While preclinical studies in rats and monkeys have shown that anacetrapib is characterized by low clearance, high degree of protein binding and high volume of distribution (Tan et al, 2010) , the data from these single-dose PK studies were unable to predict the tissue accumulation properties and the long terminal half-life observed in this study. In a previous mouse PK study where anacetrapib was given intravenously as a single dose at 0.5 mg/kg, the estimated terminal T½ values were 11 and 23 hours for WT lean and DIO mice, respectively (unpublished data).
These results were consistent with the Day 1 observed T½ in the present study, but much shorter than the T½ following the 6-week multiple dose regimen (Table 2 ). This phenomenon was also observed in humans, where single dose studies underpredicted the terminal T½ after longer-term treatment (Krishna et al, 2008; Gutstein et al, 2012) . A potential explanation is that the mechanistic causes of long terminal half-life are linked to the drug's tissue accumulation and retention characteristics. Further insight could be gained from understanding the processes that govern the entry of drug into, and release of drug out of adipose and other tissues. whereas white adipose is likely to be a major long-term depot for the drug in vivo. Brown adipose achieved the highest concentrations during the treatment period, but rapidly declined after cessation of treatment. In contrast, decline of drug levels from white adipose was much slower. It is also evident that adiposity enhances the extent of drug distribution into the adipose, as obese animals had adipose concentrations 3 to 4 times higher than lean animals. Overall, the observed high affinity of anacetrapib to adipose tissue can be explained by the lipophilicity (the reported LogD is 7.1; Merck unpublished data) and the neutral properties of the molecule.
There was an apparent slight rise in anacetrapib levels in white adipose tissue of DIO mice following cessation of dosing. This could be due to inter-animal variability, or potential redistribution from other tissues, or a combination of both. It is important to note that in the present study, epididymal white adipose tissue was sampled and used as a surrogate for the totality of white adipose tissue. We cannot preclude the possibility that different adipose depots of the body (e.g. subcutaneous, retroperitoneal, others) might exhibit differences in terms of the disposition kinetics of anacetrapib. A redistribution of drug from one depot to another is a possibility, although the mechanistic details of this process (if it does occur) are currently unknown.
It is known that white and brown adipose tissues are different with respect to their physiological functions, i.e. white adipose stores excess energy as triglycerides whereas brown adipose is specialized in the dissipation of energy through the production of heat. Also, brown adipose tissue has been shown to be metabolically active (for review, see Saely et al, 2010) . It is likely that anacetrapib, due to its lipophilicity, has a high affinity to lipid stores in adipocytes, which could help to explain the longer retention of the drug in white versus brown adipose tissue.
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Our results revealed nearly 100-fold higher Day 42 levels of anacetrapib in the livers of DIO versus lean mice. This is not entirely surprising, as the liver is a major site of lipoprotein turnover (uptake, excretion, metabolism), and anacetrapib has been shown to be associated with lipoproteins (Roddy et al, 2014) . As obesity induced by dietary fat likely increases the deposition of lipoproteins into the liver, this could cause higher hepatic drug accumulation in DIO mice.
Differences in hepatic drug metabolism between lean and DIO mice appear less plausible, since anacetrapib is a low-clearance compound, and to date there has been no evidence that adiposity would impact the extent of anacetrapib metabolism.
Despite its lipophilicity, anacetrapib did not exhibit any appreciable extent of accumulation in the mouse brain. In fact, in-house data from a brain penetration study conducted in P-gp mdr1a knockout mice indicate that anacetrapib is a P-gp substrate, as the measured brain-to-plasma AUC ratios in WT and P-gp mdr1a knockout mice were 0.015 and 0.55, respectively (unpublished). Thus the presence of P-gp at the blood-brain barrier likely limits the accumulation of free drug in the brain.
Although the impact of adiposity on anacetrapib's long terminal half-life is very clear, the role of CETP binding in this phenomenon is more complex. CETP seems to have an impact on on-treatment blood concentrations, with higher concentrations observed in NFR mice compared to WT mice. During the washout phase, blood concentrations in most WT lean animals were below limit of quantitation 24 weeks after cessation of treatment. Small but measurable amounts of drug were present in blood 35 weeks after cessation of treatment in the other three subgroups.
Approximately 7 to 11 % of Day 42 drug levels remained in the blood of WT DIO and NFR lean This article has not been copyedited and formatted. The final version may differ from this version. mice, while 25 % of Day 42 drug levels remained in NFR DIO mice. This numerical trend suggests that CETP probably has an impact on the rate of elimination of anacetrapib from blood.
On the other hand, on-treatment drug concentrations as well as elimination rates from adipose are similar for WT and NFR mice. Since CETP is present in a number of tissues including adipose, one would reasonably expect that drug binding to CETP in adipose occurs, but the relative impact of it is probably small, given the enormous capacity of adipose tissue for retaining the drug, and the large pool of drug in adipose resulting from continued accumulation solely due to its physical properties.
In CETP transgenic mice, CETP has also been shown to be expressed in tissues other than adipose, such as liver, kidney, small intestine, spleen and heart (Jiang et al, 1992) . Overall, it was found that the CETP expression levels in these mice are similar to levels in humans, and in the case of NFR mice the CETP mRNA abundance appears to be somewhat higher than in humans. Taken together, these findings support the idea that CETP is likely not a governing factor for disposition of anacetrapib into adipose tissue.
It remains to be determined whether or not the mechanisms contributing to the long terminal half-life of anacetrapib are similar to those governing the T½ of other lipophilic drugs such as amiodarone and probucol (Vadiei et al, 1997; Jeon et al, 2011) . In the case of anacetrapib, to date the long terminal half-life has not been associated with any adverse effect, and in chronic dosing anacetrapib has been shown to exhibit a favorable safety profile (Gutstein et al, 2012; Gotto et al, 2014a, b) . Several thousand patients, across a wide range of body weights, have been treated with anacetrapib for more than three years in completed or on-going clinical trials. Anacetrapib has been generally safe and well tolerated in these patients. Adipose tissue retention and long terminal half-life have so far not been linked to any safety concerns.
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